⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PTGX News
Protagonist Therapeutics, Inc
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
globenewswire.com
PTGX
SNY
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
businesswire.com
TAK
PTGX
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
globenewswire.com
CRSP
REGN
PTGX
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
PTGX
Form 8-K
sec.gov
PTGX
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
PTGX
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
businesswire.com
TAK
PTGX
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
businesswire.com
PTGX
TAK
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
accessnewswire.com
PTGX